Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.

Pharmacogenomics - 1 Nov 2012

Kulakova Olga G, Tsareva Ekaterina Yu, Boyko Alexey N, Shchur Sergey G, Gusev Evgeny I, Lvovs Dmitrijs, Favorov Alexander V, Vandenbroeck Koen, Favorova Olga O

Abstract excerpt

BACKGROUND: IFN-β is widely used as the first-line disease-modifying treatment for multiple sclerosis. However, 30-50% of multiple sclerosis patients do not respond to this therapy. Identification of genetic variants and their combinations that predict responsiveness to IFN-β could be useful for treatment prognosis. MATERIALS & METHODS: The combinations of alleles of nine polymorphic loci in immune-response genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Gene Frequency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Loci

Share to Interferon-beta

Share to Multiple Sclerosis

Share to Receptor, Interferon alpha-beta

Share to Receptors, CCR5

Share to Transforming Growth Factor beta1

Source

Identifiers

PMID: 23171334
DOI: 10.2217/pgs.12.161

Genes

CCR5
IFNAR1
IFNB1
IFNG
TGFB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.PMID 23171334Read ↗

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.Semantic proximity Read ↗

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.Semantic proximity Read ↗

Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy.Semantic proximity Read ↗

[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].Semantic proximity Read ↗

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.Semantic proximity Read ↗

Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.Semantic proximity Read ↗

Genetic Polymorphisms, their Allele Combinations and IFN-β Treatment Response in Irish Multiple Sclerosis PatientsSemantic proximity Read ↗

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment.Semantic proximity Read ↗

Three allele combinations associated with multiple sclerosis.Semantic proximity Read ↗

Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis.Semantic proximity Read ↗

Immune-Related Gene Variants as Modifiers of Multiple Sclerosis Severity.Semantic proximity Read ↗

HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.